@article{APS9448,
author = {Ruo-lan GU and Liang LIU and Liang-zhi XIE and Wen-lin GAI and Si-shuo CAO and Zhi-yun MENG and Hui GAN and Zhuo-na WU and Jian LI and Ying ZHENG and Xiao-xia ZHU and Gui-fang DOU},
title = {Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice},
journal = {Acta Pharmacologica Sinica},
volume = {37},
number = {3},
year = {2017},
keywords = {},
abstract = {Aim: SCT800 is a new third-generation recombinant FVIII agent that is undergoing promising preclinical study. This study aimed to investigate the pharmacokinetic and pharmacodynamic profiles of SCT800 in hemophilia A mice.
Methods: After hemophilia A mice were intravenously injected with single dose of SCT800 (80, 180, and 280 IU/kg) or the commercially available product Xyntha (280 IU/kg), pharmacokinetics profiles were evaluated based on measuring plasma FVIII: C. For pharmacodynamics study, dose-response curves of SCT800 and Xyntha (1–200 IU/kg) were constructed using a tail bleeding model monitoring both bleeding time and blood loss.
Results: Pharmacokinetics profile analysis showed a dose independency of SCT800 ranging from 80 to 280 IU/kg and comparable pharmacokinetic profiles between SCT800 and Xyntha at the doses tested. Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively. Moreover, at the doses tested, the accompanying dose-related safety evaluation in the tail bleeding model showed lower hypercoagulable tendency and wider dosage range potential for SCT800 than Xyntha.
Conclusion: In hemophilia A mice, SCT800 shows comparable pharmacokinetics and pharmacodynamics to Xyntha at the doses tested, and possibly with better safety properties.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9448}
}